Abstract: Pacemaking is a basic physiological process, and the cellular mechanisms involved in this function have always attracted the keen attention of investigators. The “funny” (If) current, originally described in sinoatrial node myocytes as an inward current activated on hyperpolarization to the diastolic range of voltages, has properties suitable for generating repetitive activity and for modulating spontaneous rate. The degree of activation of the funny current determines, at the end of an action potential, the steepness of phase 4 depolarization; hence, the frequency of action potential firing. Because If is controlled by intracellular cAMP and is thus activated and inhibited by β-adrenergic and muscarinic M2 receptor stimulation, respectively, it represents a basic physiological mechanism mediating autonomic regulation of heart rate. Given the complexity of the cellular processes involved in rhythmic activity, an exact quantification of the extent to which If and other mechanisms contribute to pacemaking is still a debated issue; nonetheless, a wealth of information collected since the current was first described more than 30 years ago clearly agrees to identify If as a major player in both generation of spontaneous activity and rate control. If- dependent pacemaking has recently advanced from a basic, physiologically relevant concept, as originally described, to a practical concept that has several potentially useful clinical applications and can be valuable in therapeutically relevant conditions. Typically, given their exclusive role in pacemaking, f-channels are ideal targets of drugs aiming to pharmacological control of cardiac rate. Molecules able to bind specifically to and block f-channels can thus be used as pharmacological tools for heart rate reduction with little or no adverse cardiovascular side effects. Indeed a selective f-channel inhibitor, ivabradine, is today commercially available as a tool in the treatment of stable chronic angina. Also, several loss-of-function mutations of HCN4 (hyperpolarization-activated, cyclic-nucleotide gated 4), the major constitutive subunit of f-channels in pacemaker cells, are known today to cause rhythm disturbances, such as for example inherited sinus bradycardia. Finally, gene- or cell-based methods for in situ delivery of f-channels to silent or defective cardiac muscle represent novel approaches for the development of biological pacemakers eventually able to replace electronic devices.
Self-sustained contractile activity is a fundamental cardiac function, essential for life, and it is not surprising that its features have raised the interest of researchers since the earliest attempts at describing the anatomy and physiology of the heart.
A realization of the presence of spontaneous activity can be found in the work of Claudius Galen, who in the second century AD observed that “the heart, removed from the thorax, can be seen to move for a considerable time … a definite indication that it does not need the nerves to perform its function.”1 Also, several centuries later, Leonardo da Vinci, who drew anatomic details of all organs of the body with unsurpassed draftsmanship and practiced his knowledge with dissected corpses, realized that the heart has autonomous activity. (“Del core. Questo si muove da sè, e non si ferma, se non eternalmente”: “As to the heart: it moves itself, and doth never stop, except it be for eternity” [translated by Noble2]).
A modern approach to understanding of pacemaker initiation and propagation had however to await a few more centuries, until the discovery of the bundle connecting atrium and ventricle by Wilhelm His, the atrioventricular node by Sunao Tawara, and the sinoatrial node by Arthur Keith and Martin Flack in the late 19th to early 20th century3 and the subsequent development of electrophysiological techniques.4 It is now well established that the sinoatrial node (SAN) is the natural pacemaker region of the heart, and that cells from this region underlie pacemaking. Unlike force-generating cells of the working muscle, whose main activity is mechanical, sinoatrial myocytes have the special property of self-generating repetitive action potentials and have correspondingly a poorly developed contractile system; their main function is electric, not mechanical. Action potentials originating from the central region of the sinoatrial node first propagate through the atria and then, after a slow transition across the atrioventricular node, spread through the ventricles via the specialized conduction tissue. SAN myocytes are therefore responsible for initiating spontaneous activity and controlling cardiac rate.
Given the basic relevance of pacemaking, the cellular/molecular processes underlying it have always been a major target of cardiac studies.2 What makes a SAN cell beat spontaneously? The original observation made by Galen on isolated hearts can be made today on single SAN cells, which keep beating after enzymatic isolation, as long as metabolic and environmental conditions permit; thus, although the SAN is the cardiac region most densely innervated by vagal and sympathetic nerve endings, generation of spontaneous action potentials is clearly an intrinsic property of SAN cells independent of innervation.
A distinguishing feature of spontaneously active cells, lacking in myocytes of the working muscle, is the presence in their action potential of the phase 4 diastolic (or pacemaker) depolarization. After termination of an action potential, during phase 4 the membrane voltage slowly depolarizes until it reaches threshold for firing of another action potential. Diastolic depolarization is therefore responsible for repetitive activity, and, to understand pacemaking, the interest of investigators has for obvious reasons concentrated on the mechanisms generating and controlling this phase of the action potential.
The pacemaker mechanism in heart, originally interpreted as resulting from the decay of an outward K+ current during diastolic depolarization,5 was re-evaluated in the late 70’s with the discovery in SAN cells of the “funny” current, ie, an inward current activated on hyperpolarization in the diastolic range of voltages. This provided a new interpretation of pacemaking, according to which the pacemaker depolarization was generated by activation of the inward If during diastole.6
Several data collected during more than 30 years since its discovery have provided compelling evidence that the funny current has a major role in pacemaking and rate modulation, although this concept is still strongly debated in the light of the growing complexity of cellular processes involved in all aspects of rhythm generation and maintenance.7 A deeper understanding of the molecular basis of the properties of funny channels was achieved with the cloning in the late 1990s of their molecular correlates, the HCN (hyperpolarization-activated, cyclic-nucleotide gated) channels.8–13 More recently, the interest in the concept of funny channel–based pacemaking has further grown thanks to the development of applications of this concept with a clinical relevance.
This review address the main properties of funny channels, their contribution to cardiac pacemaking and how the concept of funny channel-based pacemaking can be exploited in clinical applications. More detailed accounts of the biophysical properties of the molecular components of funny channels, the HCN channels, are given elsewhere.14,15
Physiological Evidence: If Properties Are Right for a Mechanism in Charge of Generating a Slow (Diastolic) Depolarization Process and Modulate Its Rate
General Properties
Details of the general properties of the funny current have been described in early4,16 and more recent review work7,17,18 and only essential features, and their physiological relevance are discussed here.
If was originally described in pacemaker SAN tissue.19 It is activated on hyperpolarization at voltages below about −40/−45 mV and is inward in its activation range, its reversal potential being about −10/−20 mV, a result of the mixed Na+ and K+ ionic permeability of the current later investigated.20 Because activation of an inward current leads to depolarization, the simple observation that the If activation range overlapped the range of voltages where diastolic depolarization occurs in SAN cells (approximately −40 to −65 mV) was by itself supportive of the notion that If could be a suitable candidate for generating the diastolic phase, acting therefore as a “pacemaker” current. Further reinforcing this view was evidence that If increases during perfusion with adrenaline.19If therefore appeared to have properties suitable not only for generation of spontaneous activity but also for sympathetic acceleration of rate.
IK2 Reinterpretation
The discovery of If represented the proposal of a novel mechanism, the activation of an inward current, able to explain generation of spontaneous activity, but also posed a problem, because this mechanism contrasted with a well established, apparently incontrovertible mechanism proposed more than a decade earlier to underlie pacemaker activity of Purkinje fibers: the decay of a depolarization-activated outward K+ current, the IK2 current.5 The IK2-decay hypothesis was also supported by evidence for a β adrenergic-dependent stimulation of the current able to contribute to sympathetic rate modulation.21 How was it possible that 2 completely different processes, based on currents with totally different ionic nature, could underlie pacemaker generation in 2 types of myocytes belonging to the same cardiac conduction system? The puzzle was even more baffling because to a close analysis, several features of If in SAN cells appeared to be surprisingly similar to those of IK2 in Purkinje fibers.22
Two years after the original description of If, the puzzle was solved with the reinterpretation of the ionic nature and kinetics of the IK2 current6,20: IK2 was in fact shown to be, like If, an inward current activated on hyperpolarization and carried by Na+ and K+, rather than a pure K+ current activated on depolarization. How an inward current like If could behave like a pure K+ current, with a reversal potential close to the expected K+ equilibrium potential, was explained with the presence in Purkinje fibers of a large K+ inwardly rectifying component (IK1), which decreased during the strong hyperpolarizing steps used to study IK223; the superimposition of this component with If generated a “fake” reversal potential close to the K+ equilibrium potential.
Note that SAN myocytes do not express an IK1 component,24 a property responsible for the depolarized level of diastolic depolarization in these cells; thus, an IK1-dependent K+ depletion process does not occur during voltage-clamp hyperpolarization, which explains why the inward nature of If could be promptly identified in SAN cells, but was missed in Purkinje fibers.
The use of barium to block IK1, and thus remove the IK1-dependent component, transformed the IK2 of the Purkinje fiber into If.6 This result was particularly dramatic because it unmasked the inward hyperpolarization-activated nature of IK2, an apparently pure K+ current.
The identity between the 2 “pacemaker” currents in the 2 cardiac tissues led to an integrated theory for the origin of cardiac pacemaking in different pacing regions of the heart. A systematic characterization of the funny current followed the reinterpretation of IK2 and its identification with If.2,25
Numeric Modeling
Shortly later the first If description and the reinterpretation of IK2, the novel If properties were integrated into numeric models and shown to be able to fully explain several aspects of SAN26 and Purkinje fiber16 electric activity, including the generation of diastolic depolarization and spontaneous action potentials.
The If-dependent contribution to the diastolic depolarization can be described simply on the basis of the If properties. Briefly, when during the depolarized part of the action potential, at positive voltages, If is completely turned off, no contribution is available. During repolarization however, when the voltage hyperpolarizes below about −40/−45 mV (the If activation threshold), the current switches on and progressively increases, first opposing to and then stopping the repolarization process (at the maximum diastolic potential) and finally initiating the diastolic depolarization. Action potential repolarization is driven in rabbit SAN mostly by delayed K+ current (IKr), the rapid delayed K+ current flowing through HERG channels,27 and during the last part of repolarization and the very early part of diastolic depolarization the net current will be composed primarily by a nearly equilibrated (slightly inward) sum of the inward If and the outward IKr; changes of IKr will therefore clearly be reflected by changes in the very early fraction of pacemaker depolarization, as well as during repolarization.
The If contribution terminates when, in the late part of diastolic depolarization, Ca2+-dependent processes take over and the threshold for L-type Ca2+ current activation and action potential firing is reached. Although deactivation of If at depolarized voltages is rapid, complete switch off of the current will only occur during the very early fraction of the action potential, which provides a brief time interval during which If carries an outward current at positive voltages. As is discussed below (see Figure 4), this time interval is essential for the action of specific f-channel blockers.
Figure 4. Ivabradine block of funny channels is current-dependent. The voltage dependence of If block by ivabradine 3 μmol/L (full circles at the bottom) shifts to more negative voltages (open circles), when reducing external Na+ concentration from 140 to 35 mmol/L, by approximately the same amount as the reversal potential of If (which shifts by −18.4 mV from −16 to −34.4 mV); this indicates that the voltage-dependent behavior is in fact the manifestation of a “current” dependence of block. A similar conclusion derives from the observation that the steepest change of block occurs across the reversal potential for both curves. Top, Sample traces recorded in normal and reduced Na+ concentration, as indicated, during repetitive (1/6 Hz) steps to −100 mV from a holding potential of −30 mV, in control conditions and after steady-state block by ivabradine. Data adapted from Bucchi et al.107
Autonomic Rate Modulation
The SAN of mammalians is densely innervated with autonomic nervous fibers, regulating cardiac chronotropism. Sympathetic β-adrenergic stimulation acts by accelerating, and parasympathetic muscarinic stimulation by slowing cardiac rate. As mentioned above, the original description of If in the SAN was accompanied by the finding that the current is also increased by adrenaline, in a way that could explain the accelerating action of sympathetic stimulation.19
When SAN cells are superfused with solutions containing low concentrations of adrenergic agonists, acceleration of spontaneous rate is associated with a steeper slope of diastolic depolarization, with little modification of action potential duration and shape. A post hoc analysis of data from Brown et al (1979)19 illustrates this observation for their original records, as shown in Figure 1A (right), where the trace recorded in adrenaline is shifted so as to have superimposition of control and adrenaline action potentials.
Figure 1. Low concentrations of autonomic transmitters alter rate by changing the slope of diastolic depolarization. A, Spontaneous activity recorded from a SAN preparation in a control Tyrode solution and during perfusion with 50 nmol/L adrenaline, as indicated (left) (adapted from Brown et al19); shifting horizontally the traces so as to make the upstroke of the action potentials coincide shows that most of the rate acceleration in adrenaline is attributable to steepening of the diastolic depolarization (right). B, In single-cell recordings, acceleration attributable to isoprenaline 10 nmol/L and slowing attributable to ACh 3 nmol/L also result from changes of diastolic depolarization slope, with little modification of action potential duration.
Clearly, the adrenaline-induced rate acceleration is almost entirely attributable to the shortening of the diastolic duration associated with a faster slope of diastolic depolarization, whereas only minimal changes occur in the action potential shape and duration. This agrees with the hypothesis that the process responsible for diastolic depolarization (ie, If activation) is an important target of sympathetic rate regulation.
Although the description of the If response to adrenaline was a first indication of the involvement of If in autonomic modulation of heart rate, much work was still needed to define more fully other aspects of the If function. Several additional observations provided detailed description of If features and more evidence supporting its relevance to pacemaker generation and rate control. It was shown for example that β-adrenergic receptor (AR) stimulation increases If by shifting the activation curve of the current to more positive voltages, without modification of the conductance, a result also confirmed by single-channel measurements.28,29 The depolarizing shift of If activation curve is attributable to the β-AR-dependent increase of intracellular cAMP, the second messenger in If modulation. As was later shown by macropatch analysis, cAMP positively shifts the f-channel activation curve not by a phosphorylation-dependent process, but directly by binding to channels.30 This was the first evidence, later confirmed with the cloning of HCN channels, that funny and CNG (cyclic-nucleotide gated) channels have similar properties and in fact belong to the same superfamily.
A more complete understanding of the If role in heart rate control was achieved in the mid/late 1980s, with the demonstration that If is strongly inhibited by parasympathetic stimulation, according to a mechanism opposite to that associated with β-AR stimulation, ie, a negative shift of the current activation curve attributable to muscarinic-induced inhibition of adenylate-cyclase and cAMP reduction.31,32
Vagal stimulation induces a negative chronotropic effect by releasing acetylcholine (ACh) (Figure 1B), and when the muscarinic modulation of If was discovered, the established view, based on early experiments,33 was that the mechanism responsible for ACh-induced slowing is the activation of an ACh-dependent K+ current.34 The new evidence challenged this view and raised the question whether, and to what extent, the muscarinic-dependent If inhibition was involved in the vagal-induced negative chronotropism; why should 2 different mechanisms operate simultaneously to slow cardiac rate on vagal stimulation? This question was addressed by investigating the ranges of ACh concentration required to activate the 2 mechanisms. The result was surprising, in that the concentrations were quite different: whereas low doses of ACh (up to 0.01 to 0.03 μmol/L) were shown to inhibit If, 20-fold higher concentrations were necessary to activate the K+ current conductance; also, the low doses of ACh active on If inhibition (but not on IK,ACh activation) were perfectly capable of slowing the rate of spontaneous activity of pacemaker cells (Figure 1B).35 The consequence of this finding was the introduction of a novel concept in the physiology of autonomic heart rate regulation: these results showed that the negative chronotropic effect of low-to-moderate vagal stimuli is mediated by If inhibition, not by activation of a K+ current.
Along with the cAMP-dependent modulation, other mechanisms control the function of funny channels, as shown by studies of native channels and/or individual HCN isoforms; these include accessory subunits such as MiRP1,36,37 membrane phospholipids such as PIP2 (phosphatidylinositol 4,5-bisphosphate),38 and mechanisms affecting compartmentation of channels into membrane lipid rafts.39
Phosphorylation by serine/threonine kinases (p38 mitogen-activated protein kinase)40 and by tyrosine kinases (Src) also contributes to regulate funny channel activity. The action of Src tyrosine kinase has been characterized with some detail. Phosphorylation by Src tyrosine kinase of residues Y476 (of mHCN2) or the analogous Y554 (of hHCN4), for example, was found to induce acceleration of channel activation and shift to more positive voltages the current activation curve.41,42 Specific screening of tyrosine residues of hHCN4 involved in Src-dependent phosphorylation further revealed that a major role in mediating the Src action is played by the tyrosine residue Y531.43 Src-dependent phosphorylation involves a sequence of HCN2 comprising part of the C-linker and the cyclic nucleotide binding domain, which might suggest an interaction between the actions of cAMP and phosphorylation; however, cAMP-dependent modulation is essentially preserved when Src phosphorylation is inhibited, except for a slowing of activation kinetics at saturating cAMP concentrations.41 Thus, cAMP-dependent and phosphorylation-dependent control of HCN2 appear to operate mostly through separate mechanisms.
Rate Modulation Mediated by If Involves the Rate of Diastolic Depolarization and Does Not Affect Firing Threshold
As much as low/moderate β-AR stimulation accelerates rate by promoting a steepening of diastolic depolarization, with little alteration of action potential shape and duration, so low/moderate muscarinic stimulation slows rate by a symmetrical action, ie, by decreasing diastolic depolarization rate without modification of action potential parameters (Figure 1). Detailed measurements show that neither sympathetic nor parasympathetic stimuli (when low/moderate) modify the action potential threshold.44
The specificity of action on the steepness of diastolic depolarization implies that the autonomic transmitters act mostly on the process generating and controlling this phase. Thus, showing that a specific change in If modifies only the diastolic rate would represent strong evidence that the diastolic depolarization is controlled by If activation, and that autonomic rate modulation is mediated mainly by If. Indeed, block of funny channels by “pure heart rate-reducing” agents like ivabradine (at concentrations at which they can be considered as selective) can be shown to induce slowing by reducing the diastolic depolarization rate, with little alteration of action potential duration; this subject is treated more extensively below (see the section Pharmacological Evidence).
Spontaneous activity of pacemaker cells slows down also in the presence of ryanodine, whose action involves the emptying of Ca2+ stores and inhibition of SR Ca2+ transients; this leads to the suggestion that Ca2+ cycling may represent a main mechanism for rate regulation. Changes induced by SR Ca2+ transients inhibition on action potential configuration are however quite different from those attributable to muscarinic stimulation: the early fraction of diastolic depolarization remains unaltered, and prolongation of the late fraction is associated with a substantial shift to more positive voltages of the threshold of action potential firing, a change not observed on If inhibition by ivabradine or vagal-induced slowing.7,44 These data indicate that autonomic control of chronotropism is performed via If modulation, not modulation of Ca2+ transients.7,44
The major role of If in the control of rate and its autonomic modulation at low/moderate agonist concentrations does not exclude the involvement of other components, particularly in the late fraction of diastolic depolarization, when the contribution of Ca2+ currents and the Na+/Ca2+ exchange current becomes more significant. It is worth noting in this respect that although the L-type Ca2+ current (ICa,L) has a much lower sensitivity to ACh than If, with EC50 values differing by orders of magnitude, the sensitivity to β-AR stimulation of the 2 currents is similar45; this suggests that although ICa,L does not substantially contribute to parasympathetic rate control, it may contribute, along with If, to accelerate spontaneous frequency during β-AR stimulation.
However, data concerning the contribution of ICa,L to rate control are variable. Block of ICa,L by nifedipine can lead to slowing of diastolic depolarization,46 but if applied to peripheral nodal cells, nifedipine can lead to acceleration47; also, action potential-clamp measurements show that, contrary to expectation, the nifedipine-sensitive current is outward during diastolic depolarization, possibly because of the presence of a Ca2+-dependent K+ conductance.48
A complicating factor in the analysis of the contribution of ICa,L to rate control is that changes of ICa,L normally modify action potential shape and duration and thus affect indirectly other components during activity. By acting specifically on the early fraction of diastolic depolarization without substantial alteration of action potential shape and duration (Figure 1), the funny current maintains a major, independent role in autonomic modulation of rate at low/moderate agonist concentrations.
Why Does Inhibition of Ca2+ Transients (by Ryanodine) Impair β-AR Rate Modulation?
According to the “Ca2+-clock” hypothesis, pacemaking is regulated by the periodicity of Ca2+ transients, rather than by If.49 Evidence supporting this role includes data indicating that alterations of Ca2+ cycling are reflected by changes of spontaneous frequency and rate control. It is known for example that β-AR modulation of rate is strongly inhibited in cells where exposure to ryanodine has reduced or abolished Ca2+ transients.50,51 However, it has been shown that although reducing SR Ca2+ transients does impair β-AR rate modulation, it does not affect the rate acceleration caused by increasing intracellular cAMP levels.52 This suggests that disruption of proper Ca2+ homeostasis impairs one or more of the steps leading from β-AR stimulation to rate acceleration, but is not directly involved in the cAMP/f channel-dependent mechanism of rate regulation.
Such an action could be performed for example by a Ca2+-dependent element in the cAMP signaling cascade, such as a Ca2+-activated adenylate-cyclase. As predicted,52 a Ca2+-dependent, “neuronal” form of adenylate-cyclase has indeed been recently shown to be expressed in the SAN but not in the ventricle of guinea pigs.53 The finding of a Ca2+-activated adenylate-cyclase is particularly interesting because, in addition to explaining lack of β-AR–induced rate modulation after abolishment of SR Ca2+ transients, it also provides a basis to explain early data indicating a dependence of If on intracellular Ca2+,54 although inside-out patch clamp data clearly indicated lack of a direct Ca2+ effect on f-channels.55 Ca2+ dependence of funny channels may also provide an interesting additional perspective to interpret data showing that elements involved in Ca2+ homeostasis (such as CaMKII [Ca2+/calmodulin-dependent protein kinase II]) participate in autonomic rate regulation.56
HCN Channels As Basic Components of Biopacemakers
When not responding to pharmacological treatment, life-threatening rhythm disorders such as symptomatic bradycardia, sick-sinus syndrome, atrioventricular nodal block and heart block often require the implantation of artificial pacemakers. Although electronic pacemakers are certainly effective in their function, they also have several drawbacks including lack of autonomic-driven modulation, need for a battery, etc, and in the last several years the development of biological pacemakers, potentially able to overcome these flaws, has attracted the interest of several laboratories.
Various approaches have been attempted. Gene-based methods include overexpression of β2-adrenergic receptors57,58 or of HCN channels59–64 and downregulation of K+ currents65; cell-based methods involve the transfer of spontaneously beating cardiomyocytes derived from various types of stem cells.66,67
Because funny channels have a specific role in pacemaking and do not directly affect phases of the action potential other than the diastolic depolarization, HCN-based biological pacemakers appear to be the basis for a potentially successful approach. HCN transfer has indeed proven successful in accelerating diastolic depolarization and spontaneous rate in proof-of-principle experiments where the HCN2 isoform was overexpressed in primary cultures of neonatal ventricular myocytes.59 Protocols investigated for development of HCN-based biological pacemakers include adenoviral-mediated HCN infection,60,61,63,68 chemically induced fusion of fibroblasts expressing HCN1 channels,69 and the use of mesenchymal stem cells engineered to overexpress HCN channels.62,64 Spontaneously beating human embryonic stem cell–derived cardiomyocytes have also been shown to integrate with and pace cultures of cardiac myocytes and whole hearts in vivo66,67; it is known that embryonic stem cell–derived spontaneously active myocytes express If.70–73
As a whole, these results show that the transfer of HCN channel gene or of HCN-expressing myocytes is capable under proper conditions to induce in vivo pacing.
Morphological Evidence: HCN4 Is a Marker of Pacemaker Tissue
Since the original description by Keith and Flack in 1907,74 the SAN is recognized as the cardiac region where pacemaker activity is initiated. Understandably, the most complete set of experimental data presently available from the literature was collected from laboratory animals, and particularly from the rabbit, although recent investigation has allowed to identify the expression patterns of several ion channels also in the human sinus node, at both the mRNA and protein level.75
Morphological and histological studies of the SAN show that this is a highly specialized region with features that favor the function of pacemaker generation and propagation to surrounding areas.47 Pacemaker cells have a poorly developed contractile apparatus, because their function is electric rather than mechanical, with little anisotropy so as not to favor a specific direction of propagation, although cell distribution and orientation appear to favor, if only to a limited extent, signal propagation in the direction parallel to the crista terminalis.76 Cell-to-cell coupling is poor in the SAN, which is mainly attributable to reduced density of the connexins specifically expressed in this region, typically connexin45 and connexin40 in the rabbit, dog and human SAN.47,77–79 A poor electric connection in the center of the node complemented by a progressively increasing intracellular coupling at the border with atrial muscle is thought to be functional to proper pacemaker generation, because it favors exit of the signal from the node center, limiting at the same time node hyperpolarization by atrial muscle.80
Low electric conductivity is also attributable to a paucity of excitable cells relative to connective tissue, which represents approximately 50% of whole tissue in the rabbit81 and 45% to 75% in the human SAN.82 In the rabbit, nodal myocytes are organized in nonhomogeneous clusters interconnected by thin cytoplasmic extensions forming a 3D mesh-like structure.76 This feature may be species-dependent, because in contrast with the results in the rabbit, a region characterized by a compact and almost exclusive presence of nodal myocytes has been reported in the mouse SAN.83
According to electrophysiological recordings from the mammalian SAN, the leading pacemaker site lies roughly in the area extending between the 2 venae cavae and adjacent to the crista terminalis47. Recent investigation of the distribution of expression of HCN4 in rabbit SAN has shown that HCN4 proteins are highly concentrated in the central part of the node, corresponding to the leading pacemaker site, and that their density is progressively reduced when moving to more peripheral areas (Figure 2).76 Reliability of expression data were confirmed by verification that mRNA and protein expression patterns were overlapping (Figure 2, left and right, respectively). No detectable immunofluorescence was found in the surrounding crista terminalis and septum interatrialis, confirming specific localization of pacemaker channels in the central node. Also, HCN4 membrane expression and If amplitude were correlated in cells isolated from crista terminalis, central SAN and septum interatrialis (Figure 2B through 2D).
Figure 2. HCN4 is expressed in pacing cells of the SAN region but not in atrial cells and If density correlates with degree of HCN4 expression. A, Sections of rabbit SAN tissue made by cutting according to a grid perpendicular to the crista terminalis from the superior to the inferior vena cava, with grid interval of 2 mm (top to bottom). In all slices, the crista terminalis is on the left and the interatrial septum on the right, and the endocardial surface faces up. Left images, HCN4 in situ hybridization. Right images, HCN4 immunofluorescence. Strong labeling is seen in the central area of the node, and no labeling in either crista terminalis or interatrial septum. Bars: 1 mm. B and C, Bar graphs of mean fluorescence density (measured on cell membrane only; arbitrary units) and If density (normalized to cell capacitance) in single cells isolated from crista terminalis, central SAN area, and septum interatrialis. D, Sample current traces recorded during steps to −125 (holding potential of −35 mV) from single cells enzymatically dissociated from the regions indicated. Data adapted from Brioschi et al.76
These data indicate that the region of HCN4 expression coincides with the region defined as the central node according to standard electrophysiological and morphological criteria, and that HCN4 expression, along with expression of neurofilament-M (in the rabbit) and lack of expression of atrial natriuretic peptide and connexin43, can be considered as a marker of pacemaker tissue in the adult.76
Analysis of protein expression during development also confirms the link between If and pacemaker activity. Ventricular myocytes from fetal and newborn animals contract spontaneously and express If,84,85 and disappearance of automatic rhythm and f-channel expression occurs with a similar time course.85,86
HCN4 is a pacemaker tissue marker gene. This is implied for example by developmental data, such as those indicating that in the SAN, HCN4 channel expression is stimulated by Tbx3, a transcriptional repressor whose activation is a necessary step for SAN and atrioventricular bundle development and for SAN segregation from surrounding atrial tissue.87
Evidence from hypertrophic and failing heart data also support an association between HCN4 and pacemaker activity. If is functionally inactive in adult ventricle, both because of low expression rate of HCN2 (the major ventricular HCN isoform in most animal species) and because too negative, unphysiological voltage range of activation. Expression of HCN2 (and HCN4), however, is strongly upregulated in cardiac hypertrophy and heart failure; as expected from the role of If in pacemaking, this leads to increased susceptibility to ectopic rhythm.88–92
Pharmacological Evidence
Pharmacological dissection is the gold-standard method to investigate the functional contribution of individual ion channels to specific aspects of cell electric activity. If funny channels have indeed a specific role in initiation of spontaneous activity and rate control, then pharmacological channel modulation should specifically affect the pacing rate. “Pure” heart rate reduction has been pursued for decades as a major pharmacological target by drug companies, because lowering heart rate, by decreasing oxygen demand and increasing diastolic time of myocardial perfusion, improves the prognostic outcome of cardiac diseases such as ischemic heart disease, angina and heart failure.
Elevated resting heart rate is also known as an independent predictor of cardiovascular morbidity and mortality and is associated with greater incidence of sudden cardiac death,93 reinforcing the view that heart rate-reduction per se is a potentially beneficial therapeutic approach.
In agreement with its expected role, block of If leads to rate slowing without complicating cardiovascular side effects, when block is sufficiently ion channel-specific. Several molecules are known to interact with funny channels. Early studies showed for example that external Cs+ and Rb+ ions reduce If94; these ions, however, along with other molecules also reducing If, such as THA (9-amino-1,2,3,4-tetrahydroacridine,95 clonidine,96 and propofol,97 interact with other channels and mechanisms and are far from specific. Substances able to slow heart rate by selective f-channel block were developed in the 80’s and termed “pure bradycardic agents” (PBAs). They act by depressing diastolic depolarization with little changes of other action potential parameters. Alinidine, an N-allyl derivative of clonidine, was the first PBA to be developed98; it was followed by falipamil (AQ-A39) and its congener UL-FS49 and by ZD7288.99,100 A more recently developed pure heart rate lowering agent, ivabradine, deserves special mention because it is today the only commercially available funny channel inhibitor having completed clinical development for stable angina pectoris.
The action of ivabradine is a clear indication of the role of the funny current in pacemaker activity. In vitro studies have shown that threshold concentrations of ivabradine at which effects start to be visible on the ICa,L and on the delayed K+ current (IKr) range between 3 and 10 μmol/L, whereas a half-block concentration of 2.8 μmol/L was found for If, indicating substantial selectivity.101
The presence of pure heart rate slowing, devoid of cardiovascular side effects, is a direct consequence of the selective block of funny channels by ivabradine. Indeed, ivabradine slows spontaneous rate not only when perfused in vitro onto SAN or atrial preparations or isolated SAN cells, but also when delivered in vivo through blood circulation, ie, when all cardiac myocytes experience the same drug concentration. The fact that of all mechanisms operating in the heart, the only function affected is cardiac rate demonstrates that (1) the funny current has a highly selective functional role in pacemaker generation and rate control; (2) ivabradine only interacts with funny channels; and (3) ivabradine can be properly used as a tool to slow heart rate specifically. Note that, in agreement with the above considerations, ivabradine reduces the steepness of diastolic depolarization without affecting other action potential parameters (Figure 3).
Figure 3. Action of ivabradine of If current and spontaneous rate. Left, Perfusion with ivabradine 3 μmol/L leads to progressive decrease of If recorded during repetitive steps to −100 mV·1.8 sec/+5 mV · 0.45 sec applied every 6 seconds from a holding potential of −35 mV. Top, Current records during ivabradine perfusion from control to steady-state If block. Bottom, Plotted time course of If at −100 mV (open symbols: traces plotted in top panel). Right, Slowing of spontaneous rate induced by ivabradine 1 μmol/L in another cell.
Visual disturbances (phosphenes) associated with the use of ivabradine are also attributable to block of HCN channels in the retina102; the fact that these disturbances are limited might be attributable to restricted drug access to brain circulation because of low permeability across the blood–brain barrier.103
The potential therapeutic applications of ivabradine might in fact extend beyond the treatment of stable angina, and viability for clinical use in ischemic heart disease and cardiac failure has been considered.93 The BEAUTIFUL trial (Morbidity-Mortality Evaluation of the If Inhibitor Ivabradine in Patients With Coronary Disease and Left-Ventricular Dysfunction) evaluated the action of ivabradine on a cohort of almost 11 000 CAD patients. The mean heart rate of patients treated with ivabradine (5 mg twice a day to 7.5 mg twice a day) slowed by 6 bpm relative to placebo; the study showed that in a subgroup of patients with heart rates ≥70 bpm, although primary end points (cardiovascular death, admission to hospital for new-onset or worsening heart failure) were not significantly improved, secondary end points were (admission to hospital for fatal and nonfatal myocardial infarction, coronary revascularization).104 In a more recent study (ASSOCIATE), ivabradine improved exercise tolerance and delayed the development of ischemia in chronic stable angina patients under β-blocker treatment.105 Thus, ivabradine can be used to reduce the incidence of CAD manifestations in a subgroup of high-heart rate patients.106 In all cases, it is important to stress that the efficacy of treatment with ivabradine is a consequence of its selective funny channel block and associated pure heart rate slowing effect.
The properties of ivabradine-induced block of native funny channels101,107 and of individual HCN isoforms108 have been investigated with some detail. Low concentrations of ivabradine block funny channels with a high degree of selectivity and in a use-dependent way. Block occurs at the intracellular channel side and therefore requires drug molecules to enter the cell before acting. Use dependence manifests itself as a slowly progressing block accumulation during repetitive channel activation/deactivation cycles (Figure 3) and derives from more basic properties of ivabradine action. Specifically, the If block by ivabradine: (1) is an “open channel” block, ie, channels need to be open for the drug to be able to reach the binding site within the pore; and (2) is highly voltage-dependent, being stronger at depolarized voltages.
These 2 properties are apparently in contrast, because in the first case, access to the blocking site requires hyperpolarized voltages (to open channels), and, in the second, block occurs predominantly at depolarized voltages (where channels are closed). Far from being contrasting, these properties in fact facilitate block during repetitive open/closed channel cycling. This feature has intriguing therapeutic potential because it implies that the drug effect might be stronger at high (tachycardic) rates. It is worth noting that case reports have been published indicating successful treatment of inappropriate sinus tachycardia with ivabradine.109,110
The voltage dependence of f-block (Figure 4) results from the positively charged nature of ivabradine, which carries a tertiary ammonium ion. Because they are positively charged, during a depolarization intracellular drug molecules will tend to move out of the cell across the channel and will therefore reach their binding site within the pore with higher probability.107 A unique property of ivabradine is that its blocking action is not voltage-dependent per se but is rather “current-dependent”; in other words, block efficiency depends on the direction of current flow. The results in Figure 4 show that the steady-state block caused by 3 μmol/L ivabradine during an activation/deactivation protocol (−100/−30 mV) is stronger in a low Na+ solution, when the current at −30 mV is outward, than in normal Tyrode solution, when the current at −30 mV in inward. The “current-dependent” increase of block occurring when ions flow out of the channel is caused by a “kick-in” type of effect, whereby drug molecules are pushed from the intracellular water-filled cavity toward their binding site within the pore by the outward movement of ions. The opposite “kick off” type of effect results from the inward ionic movement during hyperpolarization, which explains why hyperpolarization relieves block.107
Despite the tight correlation between selective If block and “pure” heart rate reduction, there are several limitations in the use of ivabradine (and in fact of any funny channel blocker developed so far) as a tool to quantify the exact degree of If contribution to pacemaking during activity. This is attributable to some specific features of ivabradine block. Firstly, selectivity for If block is substantial at low/moderate ivabradine concentrations, but at higher concentrations (range >3 μmol/L), other channels are affected and selectivity is lost; because the If half-block concentration is 2.8 μmol/L,101 full and simultaneously selective If blockade cannot be achieved. Secondly, even saturating concentrations of ivabradine do not block If fully, as shown in Figure 4. Thirdly, block is use-dependent, and during the repetitive channel activation/deactivation cycling associated with spontaneous activity, block will reach a steady-state level lower than maximal block; this implies that the If reduction caused by 3 μmol/L ivabradine and known to generate approximately a 30% slowing44 will certainly be, and perhaps substantially, lower than the maximal ≈60% block shown in Figure 4. Taken together, these data indicate that ivabradine cannot be used to dissect the full If contribution to pacemaker activity and that at the same time this contribution is likely to be higher than the one expected on the basis of ivabradine-induced slowing.
Block of If by ivabradine or other blockers does not abolish autonomic rate regulation,111,112 suggesting that If is not necessary for rate control. However, persistence of autonomic control of rate may be partly explained if If is not blocked fully, because under these conditions both the If responsiveness to neurotransmitters and If-mediated autonomic rate modulation are, at least partly, preserved; as discussed above this is the case with ivabradine but also, for example, with Cs+, because Cs+ (a K+-channel blocker) is unselective and blocks If only partially at diastolic voltages.99 At the same time, a contribution to autonomic rate modulation clearly also involves Ca2+ currents and the Na+/Ca2+ exchange mechanism, which play an important role in the late fraction of diastolic depolarization.113 A detailed quantification of the exact contribution of If to generation and control of pacemaker depolarization will be feasible when more highly specific and efficient funny channel blockers are available.
Genetic Evidence
The search for the genetic basis of inherited arrhythmogenic diseases has advanced rapidly since the first cardiac channelopathies were described. Channelopathies are caused by defective ion channels whose normal physiological function is impaired,114 which in the heart leads to abnormalities in electric activity and/or EC coupling.
Exhaustive clinical and experimental data exist for several well-investigated cardiac channelopathies, including different types of LQTs, short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.115
Despite their relevance to generation and maintenance of normal pacemaker activity, f-channels were not recognized as potential targets in the search for arrhythmia-related channelopathies until recently, perhaps because of the relatively late cloning of their molecular correlates, the HCN channels.18
Several genetic alterations of the open reading frame of HCN4 channel gene associated with rhythm disturbances have now been described. First reports suggesting a correlation between HCN4 mutations and rhythm disturbances described a single patient with bradycardia, atrial fibrillation, and chronotropic incompetence and atrial fibrillation116 and a small family with a complex set of pathological manifestations including syncope, severe bradycardia, LQT, and torsade des pointes. In the first case, the HCN4 mutation consisted of a heterozygous single base pair deletion (1631delC) in exon 5, which resulted in a truncated protein lacking a substantial portion of the C-terminal including the CNBD (L573X); in the second case, the HCN4 sequence revealed a missense mutation D533N. Although these reports were clearly suggestive, they did not provide compelling evidence because in the first case inheritance could not be evaluated, and in the second case the pathological phenotype was complex and a full evaluation of the significance of the correlation between HCN4 mutation and phenotype was not performed.
More complete analyses have been subsequently performed. In a large Italian family, the single-point mutation S672R of the HCN4 channel was associated with an asymptomatic bradycardic phenotype, according to an autosomal dominant type of correlation.117 In Figure 5A, the pedigree of the family investigated is shown; full/open symbols represent individuals with/without the mutation, respectively.
All wild-type family members had heart rates, measured at rest, above 60 bpm, and their mean rate was 73.2 bpm; all individuals carrying the mutation, on the other hand, had rates below 60 bpm, and their mean rate was 52.2 bpm, with a relative slowing of 29%; the expression of the mutation and the bradycardic phenotype were therefore tightly correlated (logarithm of odds score of 5.47). The S672R mutation was located near the cAMP binding site but did not affect cAMP-dependent channel activation (Figure 5B). According to in vitro experiments, the mutation was associated with a 4.9-mV hyperpolarizing shift of the activation curve of HCN4 channels relative to wild-type channels, in experiments mimicking heterozygosis, whereas experiments mimicking homozygosis yielded a shift of 8 to 9 mV (Figure 5C).117
The 4.9-mv hyperpolarizing shift caused by the heterozygous S672R mutation is an effect similar to that exerted by ACh (see Figure 1), although it does not reflect vagal hyperstimulation, but rather a constitutive new biophysical property of mutated channels. As shown in Figure 6, this effect is quantitatively adequate to slow heart rate by the amount observed within the family investigated (≈29%). Moderate ACh concentrations slow spontaneous activity of pacemaker SAN myocytes (Figure 6A) as a consequence of a shift of the current activation curve, without modification of the channel conductance31 (Figure 6B); leftward shifts (in mV) and fractional slowing of spontaneous rate are plotted in Figure 6C against ACh concentration.35 In Figure 6D, the relationship between rate slowing of SAN pacemaker cells and ACh concentration from the plots in C is shown for the 2 lowest ACh doses used to measure rates (10 and 100 nmol/L, empty bars); the slowing associated with the mutation, corresponding to a 4.9-mV negative shift of the activation curve, is also plotted (filled bar). This plot illustrates the fact that the mutation-associated negative shift of 4.9 mV, intermediate between shifts induced by 10 and 100 nmol/L ACh, causes a rate slowing in the family investigated that is intermediate between the shifts caused by the 2 ACh concentrations. This supports the view that the inheritable bradycardia described is fully attributable to the S672R-induced shift of the activation curve.
Figure 6. Comparison between rate slowing induced by the S672R hHCN4 mutation and ACh. A, Slowing of spontaneous activity (≈18% in this case) caused by ACh 10 nmol/L in a representative rabbit SAN cell. B, Double-hyperpolarizing-step protocol (−60 mV×5 sec/−95 mV×1.5 sec) shows that ACh (1 μmol/L) reduces If during the first, and increases If during the second step, in a manner that leaves unaltered the fully activated current; this means that the ACh action is to shift the If activation curve to more negative voltages, without changing the If conductance.31 C, Mean shift of the If activation curve (open circles, left axis) and mean rate slowing (full circles, right axis) in rabbit SAN cells, plotted against ACh concentration. D, Bar graph of the fractional slowing of SAN spontaneous rate caused by 10 and 100 nmol/L ACh (open bars) and that caused by the mutation (mutated vs wild-type individuals from the same family, full bar), plotted against the corresponding shifts of the If activation curve. C is replotted from DiFrancesco et al.35
Although all the 3 HCN4 mutations described above occur in the C terminus, a fourth (single-point) mutation associated with familial asymptomatic bradycardia was later found in the pore region of the channel (G480R).118 Affected family members had an average heart rate lower than 55 bpm, whereas unaffected individuals had an average rate higher than 63 bpm. The G380R mutation appeared to reduce the amount of current available for diastolic depolarization by decreasing channel synthesis and trafficking, as well as by shifting voltage dependence of activation to a more negative range.118 The mutation involves the GYG selectivity sequence typical of K+-permeable channels, and a modified permeability might therefore have been expected. However expression of mutated HCN4 channels led to a current with the same reversal potential as wild-type channels, suggesting no significant change in the Na/K permeability ratio. Another possible alteration, the channel conductance, was not investigated.
In summary, the mutations described to date in the literature may represent specific cases of a general mechanism for sinus arrhythmias based on functional defective HCN4 channels.
Conclusions
Since the first description of If, its role in underlying generation of pacemaker activity and rate control has been investigated in detail in a variety of conditions and established on the basis of several experimental findings. Recently, practical developments of the concept of If-dependent pacemaking have shown that the properties of funny channels can be exploited in clinically relevant applications. Thus, use of “heart rate–reducing” drugs such as ivabradine, which acts by selective inhibition of the If current, allows pharmacologically controlled slowing of cardiac rate, an important tool in the therapeutic approach to ischemic heart disease and other diseases whose prognosis is ameliorated by slowing heart rate. Furthermore, certain HCN4 protein mutations are associated with inheritable cardiac arrhythmias such as sinus bradycardia, suggesting the existence of a general mechanism for rhythm disorders based on altered function of funny channels. Finally, exporting funny channels to silent cardiac tissue through either gene- or cell-based protocols represents a viable tool for the future development of biological pacemakers eventually able to replace electronic ones. Further knowledge of the molecular details of funny channel structure and function will likely allow in the future a more efficient and clinically relevant approach to cardiac rate control.
Acknowledgments
I thank M. Baruscotti and A. Barbuti for assistance and A. Bucchi for providing some of the data reported here.
Sources of Funding
Supported by the European Union (normaCOR) and the Italian Ministry of Education and University and Research (FIRB RBLA035A4X).
Disclosures
None.
Footnote
Original received August 26, 2009; revision received October 13, 2009; accepted November 5, 2009.
References
1.
Siegel RE. Galen’s System of Physiology and Medicine. Basel, Switzerland: S. Karger; 1968.
Santoro B, Grant SG, Bartsch D, Kandel ER. Interactive cloning with the SH3 domain of N-src identifies a new brain specific ion channel protein, with homology to eag and cyclic nucleotide-gated channels. Proc Natl Acad Sci U S A. 1997; 94: 14815–14820.
Vaccari T, Moroni A, Rocchi M, Gorza L, Bianchi ME, Beltrame M, DiFrancesco D. The human gene coding for HCN2, a pacemaker channel of the heart. Biochim Biophys Acta. 1999; 1446: 419–425.
Ishii TM, Takano M, Xie LH, Noma A, Ohmori H. Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node. J Biol Chem. 1999; 274: 12835–12839.
Seifert R, Scholten A, Gauss R, Mincheva A, Lichter P, Kaupp UB. Molecular characterization of a slowly gating human hyperpolarization- activated channel predominantly expressed in thalamus, heart, and testis. Proc Natl Acad Sci U S A. 1999; 96: 9391–9396.
Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol. 2003; 65: 453–480.
DiFrancesco D, Noble D. A model of cardiac electrical activity incorporating ionic pumps and concentration changes. Philos Trans R Soc Lond B Biol Sci. 1985; 307: 353–398.
DiFrancesco D, Ojeda C. Properties of the current if in the sino-atrial node of the rabbit compared with those of the current IK2, in Purkinje fibres. J Physiol. 1980; 308: 353–367.
DiFrancesco D, Ohba M, Ojeda C. Measurement and significance of the reversal potential for the pace- maker current (iK2) in sheep Purkinje fibres. J Physiol. 1979; 297: 135–162.
Noble D, Noble SJ. A model of sino-atrial node electrical activity based on a modification of the DiFrancesco-Noble (1984) equations. Proc R Soc Lond B Biol Sci. 1984; 222: 295–304.
Verheijck EE, van GA, Bourier J, Bouman LN. Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. Circ Res. 1995; 76: 607–615.
DiFrancesco D, Ferroni A, Mazzanti M, Tromba C. Properties of the hyperpolarizing-activated current (if) in cells isolated from the rabbit sino-atrial node. J Physiol. 1986; 377: 61–88.
DiFrancesco D, Tromba C. Inhibition of the hyperpolarization-activated current (if) induced by acetylcholine in rabbit sino-atrial node myocytes. J Physiol. 1988; 405: 477–491.
DiFrancesco D, Tromba C. Muscarinic control of the hyperpolarization-activated current (if) in rabbit sino-atrial node myocytes. J Physiol. 1988; 405: 493–510.
Sakmann B, Noma A, Trautwein W. Acetylcholine activation of single muscarinic K+ channels in isolated pacemaker cells of the mammalian heart. Nature. 1983; 303: 250–253.
Yu H, Wu J, Potapova I, Wymore RT, Holmes B, Zuckerman J, Pan Z, Wang H, Shi W, Robinson RB, El Maghrabi MR, Benjamin W, Dixon J, McKinnon D, Cohen IS, Wymore R. MinK-related peptide 1: a beta subunit for the HCN ion channel subunit family enhances expression and speeds activation. Circ Res. 2001; 88: E84–E87.
Decher N, Bundis F, Vajna R, Steinmeyer K. KCNE2 modulates current amplitudes and activation kinetics of HCN4: Influence of KCNE family members on HCN4 currents. Pflugers Archiv. 2003; 466: 633–640.
Pian P, Bucchi A, Robinson RB, Siegelbaum SA. Regulation of gating and rundown of HCN hyperpolarization-activated channels by exogenous and endogenous PIP2. J Gen Physiol. 2006; 128: 593–604.
Arinsburg SS, Cohen IS, Yu HG. Constitutively active Src tyrosine kinase changes gating of HCN4 channels through direct binding to the channel proteins. J Cardiovasc Pharmacol. 2006; 47: 578–586.
Li CH, Zhang Q, Teng B, Mustafa SJ, Huang JY, Yu HG. Src tyrosine kinase alters gating of hyperpolarization-activated HCN4 pacemaker channel through Tyr531. Am J Physiol Cell Physiol. 2008; 294: C355–C362.
Bucchi A, Baruscotti M, Robinson RB, DiFrancesco D. Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J Mol Cell Cardiol. 2007; 43: 39–48.
Zaza A, Robinson RB, DiFrancesco D. Basal responses of the L-type Ca2+ and hyperpolarization-activated currents to autonomic agonists in the rabbit sino-atrial node. J Physiol. 1996; 491 (pt 2): 347–355.
Verheijck EE, van Ginneken AC, Wilders R, Bouman LN. Contribution of L-type Ca2+ current to electrical activity in sinoatrial nodal myocytes of rabbits. Am J Physiol. 1999; 276: H1064–H1077.
Zaza A, Micheletti M, Brioschi A, Rocchetti M. Ionic currents during sustained pacemaker activity in rabbit sino-atrial myocytes. J Physiol. 1997; 505 (pt 3): 677–688.
Maltsev VA, Lakatta EG. Dynamic interactions of an intracellular Ca2+ clock and membrane ion channel clock underlie robust initiation and regulation of cardiac pacemaker function. Cardiovasc Res. 2008; 77: 274–284.
Bucchi A, Baruscotti M, Robinson RB, DiFrancesco D. I(f)-dependent modulation of pacemaker rate mediated by cAMP in the presence of ryanodine in rabbit sino-atrial node cells. J Mol Cell Cardiol. 2003; 35: 905–913.
Hagiwara N, Irisawa H. Modulation by intracellular Ca2+ of the hyperpolarization-activated inward current in rabbit single sino-atrial node cells. J Physiol. 1989; 409: 121–141.
Zaza A, Maccaferri G, Mangoni M, DiFrancesco D. Intracellular calcium does not directly modulate cardiac pacemaker (If) channels. Pflugers Arch. 1991; 419: 662–664.
Wu Y, Gao Z, Chen B, Koval OM, Singh MV, Guan X, Hund TJ, Kutschke W, Sarma S, Grumbach IM, Wehrens XH, Mohler PJ, Song LS, Anderson ME. Calmodulin kinase II is required for fight or flight sinoatrial node physiology. Proc Natl Acad Sci U S A. 2009; 106: 5972–5977.
Edelberg JM, Aird WC, Rosenberg RD. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest. 1998; 101: 337–343.
Qu J, Plotnikov AN, Danilo P Jr, Shlapakova I, Cohen IS, Robinson RB, Rosen MR. Expression and function of a biological pacemaker in canine heart. Circulation. 2003; 107: 1106–1109.
Plotnikov AN, Sosunov EA, Qu J, Shlapakova IN, Anyukhovsky EP, Liu L, Janse MJ, Brink PR, Cohen IS, Robinson RB, Danilo P Jr, Rosen MR. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation. 2004; 109: 506–512.
Potapova I, Plotnikov A, Lu Z, Danilo P Jr, Valiunas V, Qu J, Doronin S, Zuckerman J, Shlapakova IN, Gao J, Pan Z, Herron AJ, Robinson RB, Brink PR, Rosen MR, Cohen IS. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res. 2004; 94: 952–959.
Bucchi A, Plotnikov AN, Shlapakova I, Danilo P Jr, Kryukova Y, Qu J, Lu Z, Liu H, Pan Z, Potapova I, KenKnight B, Girouard S, Cohen IS, Brink PR, Robinson RB, Rosen MR. Wild-type and mutant HCN channels in a tandem biological-electronic cardiac pacemaker. Circulation. 2006; 114: 992–999.
Plotnikov AN, Bucchi A, Shlapakova I, Danilo P Jr, Brink PR, Robinson RB, Cohen IS, Rosen MR. HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I (f) blockade. Heart Rhythm. 2008; 5: 282–288.
Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J, Gepstein L. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004; 22: 1282–1289.
Xue T, Cho HC, Akar FG, Tsang SY, Jones SP, Marban E, Tomaselli GF, Li RA. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation. 2005; 111: 11–20.
Kashiwakura Y, Cho HC, Barth AS, Azene E, Marban E. Gene transfer of a synthetic pacemaker channel into the heart: a novel strategy for biological pacing. Circulation. 2006; 114: 1682–1686.
Maltsev VA, Wobus AM, Rohwedel J, Bader M, Hescheler J. Cardiomyocytes differentiated in vitro from embryonic stem cells developmentally express cardiac-specific genes and ionic currents. Circ Res. 1994; 75: 233–244.
Hescheler J, Fleischmann BK, Lentini S, Maltsev VA, Rohwedel J, Wobus AM, Addicks K. Embryonic stem cells: a model to study structural and functional properties in cardiomyogenesis. Cardiovasc Res. 1997; 36: 149–162.
Abi-Gerges N, Ji GJ, Lu ZJ, Fischmeister R, Hescheler J, Fleischmann BK. Functional expression and regulation of the hyperpolarization activated non-selective cation current in embryonic stem cell-derived cardiomyocytes. J Physiol. 2000; 523 (pt 2): 377–389.
Barbuti A, Crespi A, Capilupo D, Mazzocchi N, Baruscotti M, DiFrancesco D. Molecular composition and functional properties of f-channels in murine embryonic stem cell-derived pacemaker cells. J Mol Cell Cardiol. 2009; 46: 343–351.
Keith A, Flack M. The form and nature of the muscular connections between the primary divisions of the vertebrate heart. J Anat Physiol. 1907; 41: 172–189.
Chandler NJ, Greener ID, Tellez JO, Inada S, Musa H, Molenaar P, DiFrancesco D, Baruscotti M, Longhi R, Anderson RH, Billeter R, Sharma V, Sigg DC, Boyett MR, Dobrzynski H. Molecular architecture of the human sinus node: insights into the function of the cardiac pacemaker. Circulation. 2009; 119: 1562–1575.
Brioschi C, Micheloni S, Tellez JO, Pisoni G, Longhi R, Moroni P, Billeter R, Barbuti A, Dobrzynski H, Boyett MR, DiFrancesco D, Baruscotti M. Distribution of the pacemaker HCN4 channel mRNA and protein in the rabbit sinoatrial node. J Mol Cell Cardiol. 2009; 47: 221–227.
Coppen SR, Kodama I, Boyett MR, Dobrzynski H, Takagishi Y, Honjo H, Yeh HI, Severs NJ. Connexin45, a major connexin of the rabbit sinoatrial node, is co-expressed with connexin43 in a restricted zone at the nodal-crista terminalis border. J Histochem Cytochem. 1999; 47: 907–918.
Davis LM, Kanter HL, Beyer EC, Saffitz JE. Distinct gap junction protein phenotypes in cardiac tissues with disparate conduction properties. J Am Coll Cardiol. 1994; 24: 1124–1132.
Davis LM, Rodefeld ME, Green K, Beyer EC, Saffitz JE. Gap junction protein phenotypes of the human heart and conduction system. J Cardiovasc Electrophysiol. 1995; 6: 813–822.
Liu J, Dobrzynski H, Yanni J, Boyett MR, Lei M. Organisation of the mouse sinoatrial node: structure and expression of HCN channels. Cardiovasc Res. 2007; 73: 729–738.
Robinson RB, Yu H, Chang F, Cohen IS. Developmental change in the voltage-dependence of the pacemaker current, if, in rat ventricle cells. Pflugers Arch. 1997; 433: 533–535.
Yasui K, Liu W, Opthof T, Kada K, Lee JK, Kamiya K, Kodama I. I(f) current and spontaneous activity in mouse embryonic ventricular myocytes. Circ Res. 2001; 88: 536–542.
Cerbai E, Pino R, Sartiani L, Mugelli A. Influence of postnatal-development on I(f) occurrence and properties in neonatal rat ventricular myocytes. Cardiovasc Res. 1999; 42: 416–423.
Hoogaars WM, Engel A, Brons JF, Verkerk AO, de Lange FJ, Wong LY, Bakker ML, Clout DE, Wakker V, Barnett P, Ravesloot JH, Moorman AF, Verheijck EE, Christoffels VM. Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. Genes Dev. 2007; 21: 1098–1112.
Cerbai E, Barbieri M, Mugelli A. Characterization of the hyperpolarization-activated current, I(f), in ventricular myocytes isolated from hypertensive rats. J Physiol. 1994; 481 (pt 3): 585–591.
Hoppe UC, Jansen E, Sudkamp M, Beuckelmann DJ. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation. 1998; 97: 55–65.
Cerbai E, Sartiani L, DePaoli P, Pino R, Maccherini M, Bizzarri F, DiCiolla F, Davoli G, Sani G, Mugelli A. The properties of the pacemaker current I(F)in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol. 2001; 33: 441–448.
Fernandez-Velasco M, Goren N, Benito G, Blanco-Rivero J, Bosca L, Delgado C. Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol. 2003; 553: 395–405.
Stillitano F, Sartiani L, DePaoli P, Mugelli A, Cerbai E. Expression of the hyperpolarization-activated current, I(f), in cultured adult rat ventricular cardiomyocytes and its modulation by hypertrophic factors. Pharmacol Res. 2008; 57: 100–109.
DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004; 64: 1757–1765.
DiFrancesco D. Block and activation of the pace-maker channel in calf purkinje fibres: effects of potassium, caesium and rubidium. J Physiol. 1982; 329: 485–507.
DiFrancesco D, Porciatti F, Janigro D, Maccaferri G, Mangoni M, Tritella T, Chang F, Cohen IS. Block of the cardiac pacemaker current (If) in the rabbit sino-atrial node and in canine Purkinje fibres by 9-amino-1,2,3,4- tetrahydroacridine. Pflugers Arch. 1991; 417: 611–615.
Knaus A, Zong X, Beetz N, Jahns R, Lohse MJ, Biel M, Hein L. Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine. Circulation. 2007; 115: 872–880.
Cacheaux LP, Topf N, Tibbs GR, Schaefer UR, Levi R, Harrison NL, Abbott GW, Goldstein PA. Impairment of hyperpolarization-activated, cyclic nucleotide-gated channel function by the intravenous general anesthetic propofol. J Pharmacol Exp Ther. 2005; 315: 517–525.
Kobinger W, Lillie C, Pichler L. N-Allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site. Naunyn Schmiedebergs Arch Pharmacol. 1979; 306: 255–262.
DiFrancesco D. Some properties of the UL-FS 49 block of the hyperpolarization- activated current (i(f)) in sino-atrial node myocytes. Pflugers Archiv. 1994; 427: 64–70.
BoSmith RE, Briggs I, Sturgess NC. Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells. Br J Pharmacol. 1993; 110: 343–349.
Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996; 118: 1051–1057.
Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 807–816.
Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009; 30: 540–548.
Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006; 572: 335–346.
Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace. 2007; 9: 1202.
Khan S, Hamid S, Rinaldi C. Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker. Pacing Clin Electrophysiol. 2009; 32: 131–133.
Noma A, Morad M, Irisawa H. Does the “pacemaker current” generate the diastolic depolarization in the rabbit SA node cells? Pflugers Arch. 1983; 397: 190–194.
Stieber J, Wieland K, Stockl G, Ludwig A, Hofmann F. Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol. 2006; 69: 1328–1337.
Vinogradova TM, Lakatta EG. Regulation of basal and reserve cardiac pacemaker function by interactions of cAMP-mediated PKA-dependent Ca2+ cycling with surface membrane channels. J Mol Cell Cardiol. 2009; 47: 456–474.
Priori SG, Napolitano C. Role of genetic analyses in cardiology. Part I: Mendelian diseases: cardiac channelopathies. Circulation. 2006; 113: 1130–1135.
Schulze-Bahr E, Neu A, Friederich P, Kaupp UB, Breithardt G, Pongs O, Isbrandt D. Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest. 2003; 111: 1537–1545.
Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med. 2006; 354: 151–157.
Nof E, Luria D, Brass D, Marek D, Lahat H, Reznik-Wolf H, Pras E, Dascal N, Eldar M, Glikson M. Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia. Circulation. 2007; 116: 463–470.
Zagotta WN, Olivier NB, Black KD, Young EC, Olson R, Gouaux E. Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature. 2003; 425: 200–205.
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.
This article is the introduction of a new thematic series on Mechanisms of Pacemaking in the Heart, which includes the following articles: Be Still, My Beating Heart – Never! [2010;106:238–239] Development of the Pacemaker Tissues of The Heart [2010;106:240–254] Mapping Cardiac Pacemaker Circuits: Methodological Puzzles of the Sinoatrial Node Optical Mapping [2010;106:255–271] The Role of The Funny Current in Pacemaker Activity Ca2+ Cycling in the Mechanism of Pacemaking Cardiac Pacemaking: Historical Overview and Future Directions Dennis Noble Guest Editor and Brian O'Rourke Editor
Authors
Affiliations
DarioDiFrancesco
From the Department of Biomolecular Sciences and Biotechnology, The PaceLab, University of Milano, Italy.
Correspondence to Dario DiFrancesco, University of Milano, Department of Biomolecular Sciences and Biotechnology, The PaceLab, via Celoria 26, 20133 Milano, Italy. E-mail [email protected]
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
The modernized classification of cardiac antiarrhythmic drugs: Its application to clinical practice, Heart Rhythm, 22, 8, (e500-e506), (2025).https://doi.org/10.1016/j.hrthm.2025.03.1997
Alectinib causes sinus bradycardia by suppressing L-type calcium current in sinus node, European Journal of Pharmacology, 998, (177527), (2025).https://doi.org/10.1016/j.ejphar.2025.177527
Should Ivabradine be First‐Line Therapy for Inappropriate Sinus Tachycardia?, Pacing and Clinical Electrophysiology, (2025).https://doi.org/10.1111/pace.15214
Recent Advances in Ionic Mechanisms in Pituitary Cells: Implications for Electrophysiological and Electropharmacological Research, Journal of Clinical Medicine, 14, 9, (3117), (2025).https://doi.org/10.3390/jcm14093117
The Role of the Funny Current in Pacemaker Activity
Circulation Research
Vol. 106
No. 3
Purchase access to this journal for 24 hours
Circulation Research
Vol. 106
No. 3
Restore your content access
Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.